181 related articles for article (PubMed ID: 24040054)
1. Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.
Sakamoto K; Nakasone H; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Ashizawa M; Sato M; Terasako-Saito K; Machishima T; Kimura S; Kikuchi M; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
PLoS One; 2013; 8(9):e73754. PubMed ID: 24040054
[TBL] [Abstract][Full Text] [Related]
2. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
[TBL] [Abstract][Full Text] [Related]
4. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
6. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.
Koehler M; St George K; Ehrlich GD; Mirro J; Neudorf SM; Rinaldo C
J Pediatr Hematol Oncol; 1997; 19(1):43-7. PubMed ID: 9065718
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
[TBL] [Abstract][Full Text] [Related]
8. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
9. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
[TBL] [Abstract][Full Text] [Related]
10. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
[TBL] [Abstract][Full Text] [Related]
13. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT.
Kanda Y; Yamashita T; Mori T; Ito T; Tajika K; Mori S; Sakura T; Hara M; Mitani K; Kurokawa M; Akashi K; Harada M
Bone Marrow Transplant; 2010 Aug; 45(8):1325-32. PubMed ID: 19966850
[TBL] [Abstract][Full Text] [Related]
15. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
17. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
[TBL] [Abstract][Full Text] [Related]
19. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation.
Kanda Y; Mineishi S; Saito T; Saito A; Ohnishi M; Niiya H; Chizuka A; Nakai K; Takeuchi T; Matsubara H; Makimoto A; Tanosaki R; Kunitoh H; Tobinai K; Takaue Y
Transplantation; 2002 Feb; 73(4):568-72. PubMed ID: 11889432
[TBL] [Abstract][Full Text] [Related]
20. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
